Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

• The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemic
• Janssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased its leadership in lung cancer across early- and late-stage disease and reinforce its biomarker-driven approach
•  Our team at PharmaShots has summarized and complied the key events of ASCO 2020

01. Roche to Present Results of Tiragolumab in P-II CITYSCAPE Study for Non-Small Cell Lung Cancer at ASCO20 #ASCO20

Date- May 14, 2020

Products- Tiragolumab

02.  AstraZeneca Reports Results of Tagrisso (osimertinib) in P-III ADAURA Study for EGFR-Mutated Lung Cancer #ASCO20

Date- May 28, 2019

Products- Tagrisso

03. AstraZeneca and Daiichi Sankyo Provide Updates of Enhertu (fam-trastuzumab deruxtecan-nxki) in HER2-Positive Metastatic Colorectal Cancer and HER2-Mutant Non-Small Cell Lung Cancer #ASCO20

Date- May 28, 2019

Products- Enhertu

04. Blueprint Medicines Highlights Durable Clinical Activity and Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors at ASCO #ASCO20

Date- May 28, 2019

Products- Pralsetinib

05. Merck’s Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-177 for Patients with MSI-H Colorectal Cancer #ASCO20

Date- May 28, 2020

Products- Keytruda

06. Forma Therapeutics Highlights Clinical Data of Olutasidenib At ASCO20 Virtual Scientific Program

Date- May 28, 2020

Product- Olutasidenib

07. Ziopharm Reports Updated Results of Ad-RTS-hIL-12 + Veledimex for Recurrent Glioblastoma  #ASCO20

Date- May 28, 2020

Products- Ad-RTS-hIL-12, Veledimex

08.  Merck KGaA and Pfizer’s Bavencio (avelumab) Demonstrates the Potential in Gestational Trophoblastic Tumors #ASCO20

Date- May 28, 2020

Products- Bavencio

09. Adaptimmune Reports Clinical Update of ADP-A2M4 for Multiple Cancer Indication ASCO20 #ASCO20

Date- May 29, 2020

Products- ADP-A2M4

10. Nanobiotix Reports First Results of NBTXR3 in P-I Expansion Study for Locally Advanced Head and Neck Cancer #ASCO20

Date- May 29, 2020

Products- NBTXR3

11. Marker Therapeutics Reports Interim Results of its MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma #ASCO20

Date- May 29, 2020

Products- N/A

12. Iovance Reports Updated Clinical Data of Lifileucel in C-144-01 Study for Advanced Melanoma #ASCO20

Date- May 29, 2020

Products- Lifileucel

13. AVEO Oncology Reports Overall Survival Results of Tivozanib in P-III TIVO-3 Study and Submitted NDA to the US FDA #ASCO20

 Date- May 29, 2020

Products- Tivozanib

14. Autolus Therapeutics Reports Additional Data of AUTO3 in P-I/II ALEXANDER Study for R/R Diffuse Large B Cell Lymphoma # ASCO20

Date- May 29, 2020

Products- AUTO3

15. Cardiff Oncology Data Reports the Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer #ASCO20

Date- May 29, 2020

Products- Onvansertib

16. Trillium Therapeutics Provides Update on the P-I Dose Escalation Study of TTI-622 #ASCO20

Date- May 29, 2020

Products- TTI-622

17. Immunogen Presents Initial Data of Mirvetuximab Soravtansine + Avastin in FORWARD II Study for Patients with Recurrent Ovarian Cancer Regardless of Platinum Status #ASCO20

 Date- May 29, 2020

Products- Mirvetuximab Soravtansine, Avastin

18. Heat Biologics Reports Positive Results of HS-110 + Nivolumab in P-II Study for Lung Cancer Trial #ASCO20

Date- May 29, 2020

Products- HS-110, Nivolumab

19. Deciphera Reports Results of Qinlock (ripretinib) in P-III INVICTUS Study for Patients with 4L Advanced GIST #ASCO20

Date- May 29, 2020

Products- Qinlock

20. Deciphera Reports Preliminary Data of Rebastinib in Combination with Paclitaxel in P-Ib/II Study for Patients with Advanced Endometrial Cancer #ASCO20

Date- May 29, 2020

Products- Rebastinib

21. Kura Oncology Reports OS Data of Tipifarnib in P-II Study for HRAS Mutant Head and Neck Squamous Cell Carcinoma

Date- May 29, 2020

Products- Tipifarnib

22. Silverback Therapeutics Reports Preclinical Data of SBT6050 as a Single Agent and in Combination with Trastuzumab to Treat HER2-Expressing Malignancies #ASCO20

Date- May 29, 2020

Products- SBT6050, Trastuzumab

23. Seattle Genetics Report Updated Results of Tukysa (tucatinib) in HER2CLIMB Study for Patients with HER2-Positive Breast Cancer with Stable or Active Brain Metastases #ASCO20

Date- May 29, 2020

Products- Tukysa

24. Gossamer Bio Reports Safety and Biomarker Data of GB1275 in P-I/II KEYNOTE-A36 Study for Selected Solid Tumors

Date- May 29, 2020

Products- GB1275

25. AstraZeneca and Daiichi Sankyo Report Results of Enhertu (trastuzumab deruxtecan) in P-II DESTINY-Gastric01 Study for HER2+ Metastatic Gastric Cancer #ASCO20

Date- May 29, 2020

Products- Enhertu

26. Athenex Reports Interim Data of Oral Paclitaxel P-II Study for Cutaneous Angiosarcoma #ASCO20

Date- May 29, 2020

Products- Paclitaxel

27. Alligator Bioscience Reports Results of ATOR-1015 in P-I Study for Metastatic Cancer #ASCO20

Date- May 29, 2020

Products- ATOR-1015

28. Treos Bio Reports Positive Final Results of PolyPEPI1018 in P-I/II Study for Microsatellite Stable Metastatic Colorectal Cancer #ASCO20

Date- May 29, 2020

Products- PolyPEPI1018

29. Myovant Sciences Reports Positive Efficacy and CV Safety Data of Relugolix in P-III HERO Study for Advanced Prostate Cancer #ASCO20

Date- May 29, 2020

Products- Relugolix

30. Janssen Divulges its Oncology Portfolio and Pipeline of Cell Therapies at ASCO20 Virtual Scientific Program #ASCO20

Date- May 29, 2020

Products- JNJ-4528, Erleada, Amivantamab, Teclistamab

31. Roche Reports Results of Alecensa in P-III ALEX Study for ALK-Positive Non-Small Cell Lung Cancer #ASCO20

Date- May 29, 2020

Product- Alecensa

32. AstraZeneca Report Results of Imfinzi (durvalumab) in P-III CASPIAN Study for 1L Extensive-Stage Small Cell Lung Cancer #ASCO20

Date- May 29, 2020

Product- Imfinzi

33. AstraZeneca Report Results of Imfinzi (durvalumab) + Tremelimumab in P-II Study 22 for Advanced Liver Cancer#ASCO20

Date- May 29, 2020

Products- Imfinzi, Tremelimumab

34. BeiGene Presents Data of Tislelizumab + CT to Treat of Patients with Advanced Squamous Non-Small Cell Lung Cancer at ASCO20 #ASCO20

Date- May 29, 2020

Product- Tislelizumab

35. Amgen Reports Clinical Data of AMG 510 in CodeBreaK 100 Study for Multiple Solid Tumors #ASCO20

Date- May 29, 2020

Product- AMG 510

36. Amphivena Reports Data from First-in-Human Study of AMV564 for Patients with Solid Tumor #ASCO 2020

Date- May 30, 2020

Products- AMV564

37. Takeda to Present Results of Iclusig (ponatinib) in P-II OPTIC Study for Chronic Myeloid Leukemia in the Chronic Phase at ASCO and EHA #ASCO20

Date- May 30, 2019

Products- Iclusig

38. Taiho Oncology Presents Data of Futibatinib in Advanced Intrahepatic Cholangiocarcinoma at #ASCO20

Date- May 31, 2020

Product- Futibatinib